REG - BioVentix PLC - Share Options Awarded

BioventixAnnouncement

Yesterday 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260420:nRST1555Ba&default-theme=true

RNS Number : 1555B  BioVentix PLC  20 April 2026

Bioventix plc

("Bioventix" or "the Company")

Share Options Awarded

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces the award on 17 April 2026 of share options
over ordinary shares in the Company (the "Options") under the Company's Share
Option Plan in 2020 to the following directors, as follows:

 Director        Position  Number of Options  Exercise Price  Total Number of Options held following this award
 Peter Harrison  CEO       32,811             £17.75          52,622
 Bruce Hiscock   CFO       9,967              £17.75          14,394

 

The Options vest between 3 and 10 years from grant and will become exercisable
once the Company recognises revenue of greater than £1.0 million, as
evidenced by audited financial statements prepared in accordance with UK GAAP,
from a commercial diagnostic partner relating to its neurological blood test
using the Company's sheep monoclonal antibody. The Options are subject to
clawback and malus provisions.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

For further information please contact:

 Bioventix plc                                              Tel: 01252 728 001

 Peter Harrison                 Chief Executive Officer

 Cavendish                                                  Tel: 020 7220 0500

 Geoff Nash / Elysia Bough      Corporate Finance

 Nigel Birks / Harriet Ward     ECM

 

 About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

 

 

The information below (set out in accordance with the requirements of UK
Market Abuse Regulation) provides further detail:

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         a)    Peter Harrison

                                                                  b)    Bruce Hiscock
 2   Reason for the notification
 a)  Position/status                                              a)    CEO

                                                                  b)    CFO
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Bioventix plc
 b)  LEI                                                          213800225MHX7LZQY108
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each

     Identification code

                                                                  GB00B4QVDF07
 b)  Nature of the transaction                                    Issue of Options

 c)  Price(s) and volume(s)                                       Exercise Price(s)           Volume(s)
     £17.75                                                                                   32,811

     £17.75                                                                                   9,967
 d)  Aggregated information

     - Aggregated volume

     - Price                                                      42,778

                                                                  £17.75

 e)  Date of the transaction                                      17 April 2026
 f)  Place of the transaction                                     Outside a trading venue
 g)  Additional Information                                       N/A

4

Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

 

GB00B4QVDF07

b)

Nature of the transaction

Issue of Options

 

c)

Price(s) and volume(s)

Exercise Price(s)

Volume(s)

£17.75

£17.75

32,811

9,967

d)

Aggregated information

- Aggregated volume

- Price

 

 

42,778

£17.75

 

e)

Date of the transaction

17 April 2026

f)

Place of the transaction

Outside a trading venue

g)

Additional Information

N/A

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSISSIIFIR



            Copyright 2019 Regulatory News Service, all rights reserved